John Turchi

Pre-steady-state binding of damaged DNA by XPC-hHR23B reveals a kinetic mechanism for damage discrimination.

Nitric oxide and cisplatin resistance: NO easy answers.

Kinetic analysis of the Ku-DNA binding activity reveals a redox-dependent alteration in protein structure that stimulates dissociation of the Ku-DNA complex.

Eukaryotic nucleotide excision repair: from understanding mechanisms to influencing biology.

ATM mediates repression of DNA end-degradation in an ATP-dependent manner.

DNA-dependent conformational changes in the Ku heterodimer.

A mechanism for DNA-PK activation requiring unique contributions from each strand of a DNA terminus and implications for microhomology-mediated nonhomologous DNA end joining.

Telomerase-associated protein 1, HSP90, and topoisomerase IIalpha associate directly with the BLM helicase in immortalized cells using ALT and modulate its helicase activity using telomeric DNA substrates.

Molecular analysis of Ku redox regulation.

Intrinsic hTRF1 fluorescence quenching reveals details of telomere DNA binding activity: impact of DNA length, structure and position of telomeric repeats.

Photo-cross-linking of XPC-Rad23B to cisplatin-damaged DNA reveals contacts with both strands of the DNA duplex and spans the DNA adduct.

Purification and characterization of exonuclease-free Artemis: Implications for DNA-PK-dependent processing of DNA termini in NHEJ-catalyzed DSB repair.

Targeted inhibition of Replication Protein A reveals cytotoxic activity, synergy with chemotherapeutic DNA-damaging agents, and insight into cellular function.

Identification of novel small molecule inhibitors of the XPA protein using in silico based screening.

Coordination of DNA-PK activation and nuclease processing of DNA termini in NHEJ.

Interrogation of nucleotide excision repair capacity: impact on platinum-based cancer therapy.

Targeting the OB-Folds of Replication Protein A with Small Molecules.

Current advances in DNA repair: regulation of enzymes and pathways involved in maintaining genomic stability.

Targeting ovarian tumor cell adhesion mediated by tissue transglutaminase.

Identification of Mre11 as a target for heat radiosensitization.

Novel irreversible small molecule inhibitors of replication protein A display single-agent activity and synergize with cisplatin.

DNA repair: from genome maintenance to biomarker and therapeutic target.

Multiple protein-protein interactions within the DNA-PK complex are mediated by the C-terminus of Ku 80.

Complex cisplatin-double strand break (DSB) lesions directly impair cellular non-homologous end-joining (NHEJ) independent of downstream damage response (DDR) pathways.

Chemotherapy induced DNA damage response: convergence of drugs and pathways.

Extracellular tissue transglutaminase activates noncanonical NF-κB signaling and promotes metastasis in ovarian cancer.

Targeting SHP2 for EGFR inhibitor resistant non-small cell lung carcinoma.

Exploring a structural protein-drug interactome for new therapeutics in lung cancer.

Unraveling the complexities of DNA-dependent protein kinase autophosphorylation.

Testing the metal of ERCC2 in predicting the response to platinum-based therapy.

The novel, small-molecule DNA methylation inhibitor SGI-110 as an ovarian cancer chemosensitizer.

Chemical inhibitor targeting the replication protein A-DNA interaction increases the efficacy of Pt-based chemotherapy in lung and ovarian cancer.

Recognition of DNA Termini by the C-Terminal Region of the Ku80 and the DNA-Dependent Protein Kinase Catalytic Subunit.

DNA repair targeted therapy: The past or future of cancer treatment?

DNA damage response (DDR) pathway engagement in cisplatin radiosensitization of non-small cell lung cancer.

Design and Structure-Guided Development of Novel Inhibitors of the Xeroderma Pigmentosum Group A (XPA) Protein-DNA Interaction.

Characterization of Thermally Activated Metalloenediyne Cytotoxicity in Human Melanoma Cells.

Small-Molecule Inhibitor Screen for DNA Repair Proteins.

Structure-Guided Optimization of Replication Protein A (RPA)-DNA Interaction Inhibitors.

Platinum-Induced Ubiquitination of Phosphorylated H2AX by RING1A Is Mediated by Replication Protein A in Ovarian Cancer.

Discovery and development of novel DNA-PK inhibitors by targeting the unique Ku-DNA interaction.

Replication gaps are a key determinant of PARP inhibitor synthetic lethality with BRCA deficiency.

OB-Folds and Genome Maintenance: Targeting Protein-DNA Interactions for Cancer Therapy.

Characterization and initial demonstration of efficacy of a novel heat-activated metalloenediyne anti-cancer agent.

Targeting Replication Protein A for Cancer Therapy.

Recent Advances in the Development of Non-PIKKs Targeting Small Molecule Inhibitors of DNA Double-Strand Break Repair.

Synthesis and Biological Evaluation of Cardiac Glycosides for Cancer Therapy by Targeting the DNA Damage Response.

Editorial: Targeting DNA repair and the DNA damage response: Beyond the standard PI3 kinase-like kinases.

ATR inhibition overcomes platinum tolerance associated with ERCC1- and p53-deficiency by inducing replication catastrophe.

Ku-DNA binding inhibitors modulate the DNA damage response in response to DNA double-strand breaks.

The mechanistic role of cardiac glycosides in DNA damage response and repair signaling.

The Effect of Replication Protein A Inhibition and Post-Translational Modification on ATR Kinase Signaling.

The effect of replication protein A inhibition and post-translational modification on ATR kinase signaling.

Impact of Optimized Ku-DNA Binding Inhibitors on the Cellular and In Vivo DNA Damage Response.